Advances in Lymphoma
Transcript: ECHELON-3: Safety and dosing schedule
Professor Wojciech Jurczak
All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.
You can't compare pears to apples and definitely CAR T-cell therapies and the regimens based on biospecific monoclonals are far better. However, if one chooses targeted chemo, ECHELON-3 proves that brentuximab vedotin is feasible and effective. We can certainly have a subgroup analysis, but practically it's not meaningful because neither cells of origin nor the level of NTC, of CD30 expression, nor the age was an important factor on which differentiating between responding and non-responding patients. It should be of notice that the therapy was effective also in dramatic cases, relapse in refractory after CAR T-cells, although in this clinical setting, biospecifics would've been of greater importance.
Now, talking about peripheral neuropathy, which is the most common adverse event, it's not very frequent, it happens in 31 out of 97 patients, most of them in grade one or two according to CTCA.
Now, we should also say that the idea of giving brentuximab vedotin three times weekly for six doses does work and is effective, as opposed to brentuximab vedotin given biweekly for 12 doses, as an original ECHELON-1 study where it was combined with AVD regimen.
The toxicity of AVD regimen, which we participated in, was much more important, and therefore, we should find alternative schedules like BrECADD, also using brentuximab vedotin was also given in six instead of 12 doses.
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event